Merck & Co Inc

NYSE:MRK   1:46:44 PM EDT
92.58
+2.17 (+2.40%)
Products

FDA Approves Updated Indication For Merck’S Keytruda (Pembrolizumab) For Treatment Of Certain Patients With Urothelial Carcinoma (Bladder Cancer)

Published: 08/31/2021 20:15 GMT
Merck & Co Inc (MRK) - FDA Approves Updated Indication for Merck’s Keytruda® (pembrolizumab) for Treatment of Certain Patients With Urothelial Carcinoma (bladder Cancer).
FDA Approves Updated Indication for Merck’s Keytruda® (pembrolizumab) for Treatment of Certain Patients With Urothelial Carcinoma (bladder Cancer).
Merck - Keytruda Approved for Treatment of Patients With Urothelial Carcinoma Who Are Not Eligible for Any Platinum-containing Chemotherapy.